Thalassemia
Conditions
Interventions
Case series:The first stage: thalidomide 25mg / day oral, treatment 3 months (12 weeks)
the second stage: first stage: thalidomide reduction of 12.5mg / day oral, treatment 3 months (12 weeks ).
Sponsors
The People's Liberation Army Joint Logistics Support Unit 923th Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with clinical and genetic diagnosis are NTDT patients; 2. Aged between 18 and 65 years old, male or female; ECOG physical strength score is 0 to 2 points; 3. Those who have received thalidomide (50mg / day) and are effective (hemoglobin rises more than 1g / dL); 4. Sign the written informed consent before the test.
Exclusion criteria
Exclusion criteria: 1. A history of blood transfusion or the use of hydroxyurea, Yisuishengxue granules and other red blood cell-increasing drugs within 3 months before the inclusion; 2. Women in pregnancy and lactation and subjects of childbearing age who do not want to take contraceptive measures; 3. Those with severe cardiopulmonary disease and abnormal liver function; with severe primary diseases such as cerebrovascular, cardiovascular, liver, kidney, and tumor; with anemia caused by other reasons, such as autoimmune hemolytic anemia; 4. Those who are allergic to the ingredients of this medicine; 5. Psychotic patients; 6. Those who participated in clinical trials of other drugs within the past month; 7. Those with a history of venous or arterial thrombosis; 8. The investigator decides that it is not suitable to participate in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin;Hemolysis index;Safety assessment; | — |
Countries
China
Contacts
Public ContactXiao-Lin Yin
The People's Liberation Army Joint Logistics Support Unit 923th Hospital
Outcome results
None listed